Search 

Bioindustry Park “Silvano Fumero” is an Italian scientific and technological park, specialized in Life Sciences, located in the Piedmont region, near Turin. Bioindustry Park promotes and develops Life Sciences research and innovation by hosting and supporting companies, start-ups and research institutions. Bioindustry Park offers a full range of services aimed at the creation and development of life sciences and health care start-up and spin-off companies not only by providing laboratories and facilities, but also through valuable scientific and business support services. Bioindustry Park “Silvano Fumero” is also the managing company of bioPmed (http://www.biopmed.eu), the Piedmont health care innovation cluster that involves private and public actors in the pharmaceutical, biotech, medtech and eHealth sectors. BioPmed gathers about 100 companies, touching the whole value chain: from research and academic institutions and foundations, to start-ups, SMEs, private and public hospitals and healthcare centers.

At Biolingus, we believe we can make life better for many people in the world, not just in rich countries, but across the globe.
BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is "inspired by nature" using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery. Our company focusses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.
BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia.
See also video made by the Swiss Chinese Chamber of Commerce : https://www.linkedin.com/posts/yvesdecadt_icbc-vischer-gunvor-activity-6737745258496434176-8BZc

Canadian IVD company with core competencies in the fields of Thrombosis, Haemostasis and oncology, with innovative technologies, we collaborate internationally with technology development companies and health-care stakeholders to develop and manufacture customized reagents and diagnostic solutions.

Bionus Biotechnology was established in 2018, with an angel investment of a Finnish Company Currently we have 15 team members, 10 full-time, and 100% master's degree or above. Bionus has in-depth cooperation with the Karolinska Institute , Tokyo Medical and Dental University and Machine Learning Tokyo, the core members of the team had the background of Nobel Prize laureate in 2018, Mr. Tasuku Honjo.

The team currently covers 2 major layouts (AI-assisted small molecule chemical drug screening and creation of new peptide vaccines), 6 types of diseases, 12 pipelines, of which the fastest is a First in class:
At present, we are looking forward to the project financing of the anti-tumor CTLA-4 novel peptide vaccine of 10 million yuan. The main usages is to complete the vaccine safety evaluation before the IND. The current anti-tumor CTLA-4 new peptide vaccine, preclinical trials have been nearly completed, and the effect is obvious. We are confident to make new technological innovations in tumor vaccines.

Who We Are

An executive search and talent acquisition specialist with a wealth of experience in the life science business sector
An alternative to the generalist search firms that offer only general search services
Able to find the right talent for you with the right approach and understanding the complexity of the life science industry
Able to build pools helping our clients to attract a long term and sustainable talent pipeline for current and future requirements, placing your company ahead of competition

Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory

Bioxis, creates biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to the aesthetic dermatology market.

Our lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and our hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.

MNC

Calciscon develops and markets diagnostic devices for the assessment of calcification- and cardiovascular risk to improve disease management of kidney patients worldwide. Our flagship product T50 is the only test capable of accurately predicting the prognosis of a kidney patient. Across 30+ peer-reviewed studies, T50 was demonstrated to accurately predict progression of vascular calcification, cardiovascular events and death. T50 is the only reliable test to individualize the treatment modality of kidney patient to improve prognosis.

CareAcross is a digital health company focusing on cancer patients, on a global scale.
It is already active in several large countries in 3 continents (Europe, Asia, Americas) including translations and localisation by custom native speakers.
We have been actively investigating the optimal path to China as a very interesting market, but also one that can benefit significantly from our services (both on the patient level, and the industry/academia/research level).